Health Care Startup BioStack Raises $9.5M in Seed Funding

BioStack, a San Francisco, CA-based provider of a data infrastructure network for healthcare and medical AI, has raised $9.5 million in a Seed funding round.

The round saw backers including Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator.

The company will use the funding to expand across the United States and international markets, develop its technology platform, and grow its engineering and research teams.

What is BioStack?

BioStack is building a data infrastructure network that connects fragmented medical records to support healthcare research and medical AI development.

Read More:Massachusetts-Based Pascal Secures $8.5M in Additional Funding

Patient information is often spread across hospitals, healthcare providers, and different technology systems. This can make it difficult to understand a patients full medical history, treatment progress and outcomes.

BioStack brings together clinical notes, laboratory results, medical images, medications, treatments, and patient outcomes to create more complete, long-term patient records.

The company de-identifies this information to develop datasets that healthcare researchers, biotechnology companies, and AI developers can use to study diseases, evaluate treatments, and train medical AI systems.

How Much Funding Has BioStack Raised?

BioStack has raised $9.5 million in seed funding. The company has not disclosed its total funding raised to date or details of any previous funding rounds.

The seed round included several investors, among them Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator.

Who Invested in BioStack’s Seed Round?

BioStack's $9.5 million seed funding round included participation from:

• Peak XV
• Afore Capital
• DCVC
• Emerson Collective
• SV Angel
• Verdict Capital
• Streamlined Ventures
• Y Combinator

Why the Funding Matters

BioStack plans to use the funding to expand its operations, develop its data infrastructure platform, and hire more engineering and research professionals.

Medical AI systems need reliable clinical data to understand diseases, evaluate treatment options, and predict patient outcomes. However, medical information is often fragmented across different systems, making it difficult to build comprehensive datasets.

Who founded BioStack?

BioStack was founded by Sanat Mishra and Parth Patwa. The company is based in San Francisco, California.

Its work focuses on connecting fragmented healthcare information and creating datasets for medical research, biotechnology, and the development and evaluation of AI systems.

"Collecting every event linked to each patient enables a view of what happens at each stage of a patient's journey," said Sanat Mishra, co-founder and CEO of BioStack. "We're building the infrastructure that connects all of the clinical information and makes it useful, both for clinicians making decisions today and for the researchers and AI developers building the future of medicine."

"The next frontier of healthcare AI will depend not only on better models, but on access to high-quality, longitudinal data that reflects how patients are treated over time," said Pushpak Kedia, Vice President, Peak XV. "Sanat and the BioStack team are building critical infrastructure that connects fragmented clinical information and transforms it into a valuable resource for clinicians, researchers and AI developers.

Market and Business Growth

BioStack's data network spans the United States, India, Brazil, and Argentina. The company says it covers more than 100 million de-identified patient records.

Its dataset combines clinical records with several hundred thousand X-rays, MRI scans, and CT scans, along with other pathology and medical information.

BioStacks platform serves healthcare and biotechnology companies, researchers and developers working on medical AI. The company plans to expand its presence in the United States and international markets.

What Happens Next?

BioStack plans to continue expanding its data network, improve its technology platform, and grow its engineering and research teams.

The company aims to connect more clinical information across healthcare systems and build datasets that support medical research and AI development.

Read More: Michigan-Based Ultra Security Secures $10M in Seed Funding